- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mallinckrodt to distribute Myoview
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of restricted blood supply to the heart muscle, according to the company.
Mallinckrodt of St. Louis and Medi-Physics of Arlington Heights, IL, will both provide the agent in the U.S. The agreement also includes a five-year extension.
In other Mallinckrodt news, the company has jointly announced with Molecular Biosystems that MBI's FS069 second-generation ultrasound contrast agent has been given the brand name Optison. Regulatory activity by the Food and Drug Administration on that agent has been temporarily halted following a U.S. District Court preliminary injunction on April 21 (SCAN 4/30/97).
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
